Navigation Links
Enzyme complex could be key to new cancer treatments

Penn State scientists are the first to observe in living cells a key step in the creation of adenine and guanine, two of the four building blocks that comprise DNA. Also called purines, the two building blocks are essential for cell replication. The findings, which will be published in the 4 April 2008 issue of the journal Science, could lead to new cancer treatments that prevent cancer cells from replicating by interfering with their abilities to make purines.

The group used cervical cancer cells--which have an increased demand for purines due to their rapid rates of replication--to demonstrate that a group of six enzymes is involved in the creation of purines. "Our research shows that these enzymes form a cluster prior to purine formation," said Erin Sheets, an assistant professor of chemistry and a collaborator on the project.

Although other researchers had, in the past, studied the enzymes individually in test tubes, no one, until now, had examined the group of enzymes together in living cells. "This is the first time that anyone has used the appropriate technology to look for this kind of complex in a living cell," said the team's leader Stephen Benkovic, Evan Pugh Professor of Chemistry and holder of the Eberly Family Chair in Chemistry.

Postdoctoral associates Songon An and Ravindra Kumar, from the Benkovic group, studied the enzyme clusters using a technique called fluorescence microscopy, in which fluorescent proteins are attached to molecules of interest and viewed under a special microscope. According to Sheets, the technique makes it easier to observe specific molecules in a cell. "It's like giving a bright orange helmet to your favorite football player so you can more easily monitor his actions," she said.

The researchers attached fluorescent proteins to the enzymes of cells grown in the presence and absence of purines. They found that in the absence of purines, enzymes formed clusters at much higher rates, suggesting that they play a role in the creation of new purines. In contrast, cells also can produce purines by recycling old purine material. Owing to this salvage process, cells do not always need enzyme clusters; indeed, cluster formation was not observed in cells that were grown in the presence of purines. In a key experiment, the researchers were able to influence the association and dissociation of the enzyme cluster by changing the cells' exposure to purines.

Not all of the cells that were grown in the absence of purines contained enzyme clusters. "We think that the enzymes form clusters only when a cell needs purines, and that happens when a cell is required to replicate its DNA at a certain stage in its cell cycle," said Sheets. "Since each of our samples contain cells at different stages of the cell cycle, we did not expect all of them to be actively replicating their DNA. Therefore, we weren't surprised to find that some of our cells did not contain enzyme clusters."

Because purines are necessary for DNA replication and, ultimately, for cell replication, the ability to halt purine synthesis could prove to be a valuable method for treating cancer. "Cancer cells have very high demands for purines," said Benkovic. "If we can find a way to disrupt the formation of this particular enzyme cluster, it could become a potential new target for cancer therapy."


Contact: Barbara K. Kennedy
Penn State

Related medicine news :

1. Elevated liver enzymes associated with higher future mortality
2. Enzyme structure reveals new drug targets for cancer and other diseases
3. Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
4. AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and Enhances DNA Repair
5. First look at an enzyme target for antibacterial and cancer drugs
6. Caught in the act: The dynamic dance of enzymes
7. McGill researchers link enzyme to breast cancer malignancy
8. Telomerase enzyme structure provides significant new target for anti-cancer therapies
9. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
10. Role of a key enzyme in reducing heart disease identified
11. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
Post Your Comments:
Related Image:
Enzyme complex could be key to new cancer treatments
(Date:12/1/2015)... ... December 01, 2015 , ... On Tuesday 27 Oct ... to educate the personnel on spinal decompression therapy and offer his professional help. ... procedure. The benefits come from creating negative intradiscal pressure which is conducive to ...
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced the ... System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a global ... their ability to work and be productive, to do simple daily activities like walking ...
(Date:12/1/2015)... ... December 01, 2015 , ... The North American Meat ... that meat and poultry play in a healthy, balanced diet. , includes ... visitors can check their “meat IQ,” a section offering straight talk on controversies, ...
(Date:12/1/2015)... ... December 01, 2015 , ... World Patent Marketing , a vertically ... patent that allows for easier packing and organizing of items into one big, portable ... says Scott Cooper, CEO and Creative Director of World Patent Marketing and Desa ...
(Date:12/1/2015)... ... December 01, 2015 , ... Henderson, a town of about ... Internet through a partnership this year with Aeneas Internet and Telephone. , With ... destination for entrepreneurs who want to build a business. Whether startups or long ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... -- A large study of patients with breast cancer who ... found no increased risk of recurrence. The Kaiser Permanente ... National Cancer Institute. --> ... drug taken by women with breast cancer to reduce ... for five years, but has notable side effects, including ...
(Date:12/1/2015)... BOTHELL Wash. and VANCOUVER ... Monitoring Committee (DMC) meeting, OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... trial is continuing based on the pre-planned interim futility ... safety review, no new safety issues were identified by ... to all analyses and final results are expected in ...
(Date:12/1/2015)... HERNDON, Va. , Dec. 1, 2015 ... (FDA) Drug Supply Chain Security Act (DSCSA) approaches, ... helping small and independent pharmacies comply with looming ... --> InfiniTrak is entering endorsement agreements with ... a pharmacy services administration organization (PSAO) to exclusively ...
Breaking Medicine Technology: